Y. Zuo

发表

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study.

B. Han, G. Jiang, H. Pan, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Aggressive intraoperative warming versus routine thermal management during non-cardiac surgery (PROTECT): a multicentre, parallel group, superiority trial

E. Mascha, P. J. Devereaux, Yuguang Huang, 2022, The Lancet.

Phase I dose-escalating study of S-1 in combination with oxaliplatin for patients with advanced and/or metastatic colorectal cancer

Xiao-dong Zhu, Jin Li, Y. Zuo, 2008, Anti-cancer drugs.

Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies

Jin Li, Jun Qian, Y. Zuo, 2010, BMC Cancer.

Empagliflozin Protects against Pulmonary Ischemia/Reperfusion Injury via an ERK1/2-Dependent Mechanism

Y. Zuo, Zhaoyang Hu, G. Abbott, 2021 .

Single- and multiple-dose pharmacokinetics, safety and tolerability of zibotentan (ZD4054) in Chinese men with advanced solid tumors

M. Ranson, Jin Li, Jun Qian, 2012, Cancer Chemotherapy and Pharmacology.

Methylprednisolone in patients undergoing cardiopulmonary bypass (SIRS): a randomised, double-blind, placebo-controlled trial

S. Yusuf, Á. Avezum, J. Pogue, 2015, The Lancet.

Characterization of PD-L1 expression in Chinese non-small cell lung cancer patients with PTEN expression as a means for tissue quality screening

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2018, Cancer Immunology, Immunotherapy.

Clinical Features of Suspected Malignant Hyperthermia in China from 2015 to 2020: A Retrospective Study from China Malignant Hyperthermia Emergency Assistance Group

Y. Zuo, Hongfeng Yu, Y. Teng, 2022, Journal of multidisciplinary healthcare.

Characterization of plasma metabolites and proteins in patients with herpetic neuralgia and development of machine learning predictive models based on metabolomic profiling

Rui-Hao Zhou, Y. Zuo, Jun Li, 2022, Frontiers in Molecular Neuroscience.

Steroids In caRdiac Surgery (SIRS) trial: acute kidney injury substudy protocol of an international randomised controlled trial

S. Yusuf, J. Pogue, A. Garg, 2014, BMJ Open.

Primary Small Intestinal Malignant Tumors: Survival Analysis of 48 Postoperative Patients

Y. Zuo, F. Lv, Jin Li, 2008, Journal of clinical gastroenterology.

AdvanTIG-202: A phase 2 study investigating anti-TIGIT monoclonal antibody ociperlimab plus anti-PD-1 monoclonal antibody tislelizumab in patients with previously treated recurrent or metastatic cervical cancer.

Chih-Long Chang, Y. Zuo, H. Kim, 2021 .

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study.

B. Han, G. Jiang, H. Pan, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Characterization of PD-L1 expression in Chinese non-small cell lung cancer patients with PTEN expression as a means for tissue quality screening

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2018, Cancer Immunology, Immunotherapy.